CLS 2210, hyaluronidase and the cardiac lymphatic system.
Earlier studies have shown that hyaluronidase exerts a potent influence upon the lymphatic system of the myocardium and that it reduces the size of myocardial infarcts after coronary occlusion. In this study we compared, in mongrel dogs, the effect of intravenous hyaluronidase or CLS 2210 upon the cardiac lymphatic vessels. We observed that in CLS 2210-treated animals the number of visualized cardiac lymphatic vessels was significantly higher than in the hyaluronidase-treated control group. We have previously demonstrated a cardioprotective effect of hyaluronidase in the treatment of acute myocardial infarction. The present experimental data indicate that intravenous CLS 2210 may have a definite role in the management of acute coronary occlusion. Further studies are needed to confirm these preliminary findings.
D000818:Animals; D001557:Benzenesulfonates / Q000494:pharmacology*; D003327:Coronary Disease / Q000188:drug therapy / Q000503:physiopathology; D004285:Dogs; D005260:Female; D006321:Heart / Q000187:drug effects*; D006821:Hyaluronoglucosaminidase / Q000494:pharmacology* / Q000627:therapeutic use; D008208:Lymphatic System / Q000187:drug effects* / Q000502:physiology; D008220:Lymphography; D008297:Male
D001557:Benzenesulfonates; C046114:CLS 2210; D006821:Hyaluronoglucosaminidase